Literature DB >> 27793569

Dendritic Cells and Cancer Immunity.

Alycia Gardner1, Brian Ruffell2.   

Abstract

Dendritic cells (DCs) are central regulators of the adaptive immune response, and as such are necessary for T-cell-mediated cancer immunity. In particular, antitumoral responses depend on a specialized subset of conventional DCs that transport tumor antigens to draining lymph nodes and cross-present antigen to activate cytotoxic T lymphocytes. DC maturation is necessary to provide costimulatory signals to T cells, but while DC maturation occurs within tumors, it is often insufficient to induce potent immunity, particularly in light of suppressive mechanisms within tumors. Bypassing suppressive pathways or directly activating DCs can unleash a T-cell response, and although clinical efficacy has proven elusive, therapeutic targeting of DCs continues to hold translational potential in combinatorial approaches. Copyright Â
© 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  antigen presentation; cancer; dendritic cells; immunotherapy; tumor microenvironment; vaccination

Mesh:

Substances:

Year:  2016        PMID: 27793569      PMCID: PMC5135568          DOI: 10.1016/j.it.2016.09.006

Source DB:  PubMed          Journal:  Trends Immunol        ISSN: 1471-4906            Impact factor:   16.687


  100 in total

Review 1.  Dendritic cells: specialized and regulated antigen processing machines.

Authors:  I Mellman; R M Steinman
Journal:  Cell       Date:  2001-08-10       Impact factor: 41.582

2.  Safety and survival with GVAX pancreas prime and Listeria Monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer.

Authors:  Dung T Le; Andrea Wang-Gillam; Vincent Picozzi; Tim F Greten; Todd Crocenzi; Gregory Springett; Michael Morse; Herbert Zeh; Deirdre Cohen; Robert L Fine; Beth Onners; Jennifer N Uram; Daniel A Laheru; Eric R Lutz; Sara Solt; Aimee Luck Murphy; Justin Skoble; Ed Lemmens; John Grous; Thomas Dubensky; Dirk G Brockstedt; Elizabeth M Jaffee
Journal:  J Clin Oncol       Date:  2015-01-12       Impact factor: 44.544

3.  Toll-like Receptor 2 Activation Promotes Tumor Dendritic Cell Dysfunction by Regulating IL-6 and IL-10 Receptor Signaling.

Authors:  Michael Tang; Jun Diao; Hongtao Gu; Ismat Khatri; Jun Zhao; Mark S Cattral
Journal:  Cell Rep       Date:  2015-12-17       Impact factor: 9.423

4.  The purinergic receptor P2Y2 receptor mediates chemotaxis of dendritic cells and eosinophils in allergic lung inflammation.

Authors:  T Müller; B Robaye; R P Vieira; D Ferrari; M Grimm; T Jakob; S F Martin; F Di Virgilio; J-M Boeynaems; J C Virchow; M Idzko
Journal:  Allergy       Date:  2010-09-29       Impact factor: 13.146

Review 5.  The multifaceted biology of plasmacytoid dendritic cells.

Authors:  Melissa Swiecki; Marco Colonna
Journal:  Nat Rev Immunol       Date:  2015-07-10       Impact factor: 53.106

6.  Cytokine levels correlate with immune cell infiltration after anti-VEGF therapy in preclinical mouse models of breast cancer.

Authors:  Christina L Roland; Kristi D Lynn; Jason E Toombs; Sean P Dineen; D Gomika Udugamasooriya; Rolf A Brekken
Journal:  PLoS One       Date:  2009-11-03       Impact factor: 3.240

7.  Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors.

Authors:  François Ghiringhelli; Lionel Apetoh; Antoine Tesniere; Laetitia Aymeric; Yuting Ma; Carla Ortiz; Karim Vermaelen; Theocharis Panaretakis; Grégoire Mignot; Evelyn Ullrich; Jean-Luc Perfettini; Frédéric Schlemmer; Ezgi Tasdemir; Martin Uhl; Pierre Génin; Ahmet Civas; Bernhard Ryffel; Jean Kanellopoulos; Jürg Tschopp; Fabrice André; Rosette Lidereau; Nicole M McLaughlin; Nicole M Haynes; Mark J Smyth; Guido Kroemer; Laurence Zitvogel
Journal:  Nat Med       Date:  2009-09-20       Impact factor: 53.440

Review 8.  Dendritic-cell-based therapeutic cancer vaccines.

Authors:  Karolina Palucka; Jacques Banchereau
Journal:  Immunity       Date:  2013-07-25       Impact factor: 31.745

9.  Bystander killing of cancer requires the cooperation of CD4(+) and CD8(+) T cells during the effector phase.

Authors:  Andrea Schietinger; Mary Philip; Rebecca B Liu; Karin Schreiber; Hans Schreiber
Journal:  J Exp Med       Date:  2010-10-04       Impact factor: 14.307

10.  Reversal of tumor-induced dendritic cell paralysis by CpG immunostimulatory oligonucleotide and anti-interleukin 10 receptor antibody.

Authors:  Alain P Vicari; Claudia Chiodoni; Céline Vaure; Smina Aït-Yahia; Christophe Dercamp; Fabien Matsos; Olivier Reynard; Catherine Taverne; Philippe Merle; Mario P Colombo; Anne O'Garra; Giorgio Trinchieri; Christophe Caux
Journal:  J Exp Med       Date:  2002-08-19       Impact factor: 14.307

View more
  216 in total

1.  Impact of tumor-infiltrating LAMP-3 dendritic cells on the prognosis of esophageal squamous cell carcinoma.

Authors:  Junya Nishimura; Hiroaki Tanaka; Yoshihito Yamakoshi; Soichiro Hiramatsu; Tatsuro Tamura; Takahiro Toyokawa; Kazuya Muguruma; Kiyoshi Maeda; Kosei Hirakawa; Masaichi Ohira
Journal:  Esophagus       Date:  2019-04-09       Impact factor: 4.230

Review 2.  Current concept for tertiary lymphoid structures in urothelial carcinoma of the bladder: a literature review and our experience.

Authors:  Milena Gulinac; Dorian Dikov; Simeon Lichev; Tsvetelina Velikova
Journal:  Am J Clin Exp Immunol       Date:  2020-12-15

3.  NaCl Nanoparticles as a Cancer Therapeutic.

Authors:  Wen Jiang; Lei Yin; Hongmin Chen; Amy Victoria Paschall; Liuyang Zhang; Wenyan Fu; Weizhong Zhang; Trever Todd; Kevin Shengyang Yu; Shiyi Zhou; Zipeng Zhen; Michael Butler; Li Yao; Feng Zhang; Ye Shen; Zibo Li; Amelia Yin; Hang Yin; Xianqiao Wang; Fikri Y Avci; Xiaozhong Yu; Jin Xie
Journal:  Adv Mater       Date:  2019-09-25       Impact factor: 30.849

Review 4.  Nanotechnology based therapeutic application in cancer diagnosis and therapy.

Authors:  Ragini Singh
Journal:  3 Biotech       Date:  2019-10-23       Impact factor: 2.406

Review 5.  The interplay between innate and adaptive immunity in cancer shapes the productivity of cancer immunosurveillance.

Authors:  Renee B Chang; Gregory L Beatty
Journal:  J Leukoc Biol       Date:  2020-04-09       Impact factor: 4.962

6.  Induction of Immunogenic Cell Death of Esophageal Squamous Cell Carcinoma by 5-Fluorouracil and Cisplatin.

Authors:  Junya Nishimura; Sota Deguchi; Hiroaki Tanaka; Yoshihito Yamakoshi; Mami Yoshii; Tatsuro Tamura; Takahiro Toyokawa; Shigeru Lee; Kazuya Muguruma; Masaichi Ohira
Journal:  In Vivo       Date:  2021 Mar-Apr       Impact factor: 2.155

7.  The Tumor Microenvironment of Bladder Cancer.

Authors:  Ken Hatogai; Randy F Sweis
Journal:  Adv Exp Med Biol       Date:  2020       Impact factor: 2.622

Review 8.  Image-guided dendritic cell-based vaccine immunotherapy in murine carcinoma models.

Authors:  Bin Wang; Chong Sun; Sijia Wang; Na Shang; Matteo Figini; Quanhong Ma; Shanzhi Gu; Daniele Procissi; Vahid Yaghmai; Guoxin Li; Andrew Larson; Zhuoli Zhang
Journal:  Am J Transl Res       Date:  2017-10-15       Impact factor: 4.060

9.  The non-linearity of RAF-MEK signaling in dendritic cells.

Authors:  Kristina Riegel; Krishnaraj Rajalingam
Journal:  Cell Cycle       Date:  2020-08-04       Impact factor: 4.534

10.  An immune-related gene signature for predicting survival and immunotherapy efficacy in hepatocellular carcinoma.

Authors:  Yifei Dai; Weijie Qiang; Kequan Lin; Yu Gui; Xun Lan; Dong Wang
Journal:  Cancer Immunol Immunother       Date:  2020-10-21       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.